InMed Pharmaceuticals Statistics
Want to see INM full AI Analyst Report?
InMed Pharmaceuticals (INM) Stock Statistics & Valuation Metrics
Total Valuation
InMed Pharmaceuticals has a market cap or net worth of $6.70M. The enterprise value is $6.30M.
- Market Cap
- $6.70M
- Enterprise Value
- $6.30M
Share Statistics
InMed Pharmaceuticals has 549,374 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 549,374
- Owned by Insiders
- 39.34%
- Owned by Institutions
- ―
Financial Efficiency
InMed Pharmaceuticals’s return on equity (ROE) is -11.68 and return on invested capital (ROIC) is -920.47%.
- Return on Equity (ROE)
- -11.68
- Return on Assets (ROA)
- -4.15
- Return on Invested Capital (ROIC)
- -920.47%
- Return on Capital Employed (ROCE)
- -9.20
- Revenue Per Employee
- 529.42M
- Profits Per Employee
- -2.09M
- Employee Count
- 6
- Asset Turnover
- 1048.33
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of InMed Pharmaceuticals is -0.50. InMed Pharmaceuticals’s PEG ratio is -0.01.
- PE Ratio
- -0.50
- PS Ratio
- 0.00
- PB Ratio
- -7.10
- Price to FCF
- -0.95
- Price to Operating Cash Flow
- -0.94
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, InMed Pharmaceuticals had revenue of 3.18B and earned -12.56M in profits. Earnings per share was -31.20.
- Revenue
- 3.18B
- Gross Profit
- 709.84M
- Operating Income
- -9.90M
- Pretax Income
- -11.37M
- Net Income
- -12.56M
- EBITDA
- -9.19M
- Earnings Per Share (EPS)
- -31.20
Cash Flow
In the last 12 months, operating cash flow was -9.04M and capital expenditures 9, giving a free cash flow of -9.04M billion.
- Operating Cash Flow
- -9.04M
- Free Cash Flow
- -9.04M
- Free Cash Flow per Share
- -16.52
Dividends & Yields
InMed Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -105.72%
- Earnings Yield
- -145.82%
Stock Price Statistics
- Beta
- 2.96
- 52-Week Price Change
- -10.29%
- 50-Day Moving Average
- 13.95
- 200-Day Moving Average
- 12.20
- Relative Strength Index (RSI)
- 52.95
- Average Volume (3m)
- 10.10K
Important Dates
InMed Pharmaceuticals upcoming earnings date is Feb 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 03, 2026
- Next Earnings Date
- Feb 16, 2027
- Ex-Dividend Date
- ―
Financial Position
InMed Pharmaceuticals as a current ratio of 1.37, with Debt / Equity ratio of 0.00%
- Current Ratio
- 1.37
- Quick Ratio
- 1.37
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.24
- Interest Coverage Ratio
- -924.78
Taxes
In the past 12 months, InMed Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
InMed Pharmaceuticals EV to EBITDA ratio is 116.62, with an EV/FCF ratio of 120.16.
- EV to Sales
- -0.53
- EV to EBITDA
- 116.62
- EV to Free Cash Flow
- 120.16
- EV to Operating Cash Flow
- 120.16
Balance Sheet
InMed Pharmaceuticals has $1.13B in cash and marketable securities with $0.00 in debt, giving a net cash position of $1.13B billion.
- Cash & Marketable Securities
- $1.13B
- Total Debt
- $0.00
- Net Cash
- $1.13B
- Net Cash Per Share
- $2,065.66
- Tangible Book Value Per Share
- -$2.19
Margins
Gross margin is 14.90%, with operating margin of -0.49%, and net profit margin of -0.60%.
- Gross Margin
- 14.90%
- Operating Margin
- -0.49%
- Pretax Margin
- -0.57%
- Net Profit Margin
- -0.60%
- EBITDA Margin
- -0.45%
- EBIT Margin
- -0.49%
Analyst Forecast
The average price target for InMed Pharmaceuticals is $34.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $34.00
- Price Target Upside
- ―
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- -82.91%
- EPS Growth Forecast
- 55.05%
Scores
- Smart Score
- ―
- AI Score
- 50
